In fact, the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has been approved as a first-line treatment in patients with BRAF V600E mutated melanoma in the US and Europe. This evidence concerns the gene MAP2K7 and melanoma.